Industry-Academia Synergy: NIPER Raebareli Inks Landmark Biotech Agreements with Lofty Laboratories

Date:

Share post:

National Institute of Pharmaceutical Education and Research, Raebareli has entered into a strategic collaboration with Lofty Laboratories through the signing of a Memorandum of Understanding (MoU), Confidential Disclosure Agreement (CDA), and Technology Transfer Agreement aimed at accelerating indigenous biotechnology innovation and commercialization.

The partnership reflects a growing industry-academia synergy focused on translating research-driven innovations into commercially viable healthcare solutions. Through this collaboration, both organisations aim to strengthen technology development, facilitate knowledge exchange, and promote the commercialisation of homegrown biotech technologies in India.

The agreements are expected to support collaborative research initiatives, industrial training opportunities, and faster transfer of scientific advancements from laboratory to market. The initiative also aligns with India’s broader vision of strengthening self-reliance in pharmaceuticals and biotechnology under the “Make in India” and innovation-driven healthcare ecosystem.

The collaboration marks another important step toward building a robust and innovation-oriented biotechnology sector in the country.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related articles

Dabur India Plant Under US FDA Scanner Over Contamination Concerns

The United States Food and Drug Administration (US FDA) has flagged serious concerns at Dabur India's manufacturing facility...

FDA Approves Wockhardt’s Novel Antibiotic ZAYNICH™️ for cUTI

Wockhardt Limited  announced that the U.S. Food and Drug Administration (FDA) has approved ZAYNICH™ (cefepimeand zidebactam), a novel intravenous antibiotic...

Relief for Patients: NPPA Fixes Ceiling Prices for 30 Essential Medicines

The National Pharmaceutical Pricing Authority (NPPA) has notified ceiling prices for 30 essential fixed-dose combination medicines under the...

FDA Draft Guidance Aims to Reduce Animal Testing for Cancer Drugs

The U.S. Food and Drug Administration (FDA) issued a new draft guidance aimed at reducing unnecessary animal testing...